Fascaplysin
CDK4 inhibitor / A novel marine natural product isolated from Thorectandra sp1. A potent and selective inhibitor of cyclin dependent kinase 4/cyclin D1 (IC50 = 0.35 μM) and is less selective for Cdk6/D1 (IC50 = 3.4 μM). Displays antiangiogenic acitivity2. Displays high cytotoxic activity against small cell lung cancer cell lines acting via multiple mechanisms including topoisomerase I, DNA integrity and ROS3.
Biochemicals & reagents
114719-57-2
1) Soni et al. (2000), Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product; Biochem. Biophys. Res. Commun., 275 877 2) Lin et al. (2007), Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo; Cancer Chemother. Pharmacol., 59 439 3) Hamilton et al. (2014), Cytotoxic effects of fascaplysin against small cell lung cancer cell lines; Mar. Drugs, 12 1377
-20°C
TARGET: Kinase -- PATHWAY: Cytotoxicity -- RESEARCH AREA: Angiogenesis; Cell death -- DISEASE AREA: Cancer